Impureses d'aminoàcids utilitzats per sintetitzar proteïnes
Detall del producte
| NO | Productes | CAS NO | Indicador de qualitat clau | |||
| Puresa | Màxim. impuresa | Residu total de dissolvents | Humitat | |||
| 1 | FMOC-β-Ala-Ala-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 2 | Fmoc-d-ala-d-ala-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-Ala-D-Ala-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 4 | Fmoc-arg (pbf) -arg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 5 | FMOC-β-Ala-Arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 6 | Fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 7 | FMOC-β-Ala-D-Arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-Homoarg (PBF) -Homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 9 | FMOC-β-Ala-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-Ala-asn (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 12 | Fmoc-as (otbu) -asp (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 13 | Fmoc-β-Ala-ASP (OTBU) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 15 | Fmoc-β-Ala-Cys (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 16 | Fmoc-Cys (ACM) -Cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 19 | Fmoc-β-Ala-Gln (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 20 | Fmoc-glu (otbu) -Glu (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 21 | FMOC-β-Ala-Glu (OTBU) -OH.H2O | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 22 | Fmoc-β-Ala-Gly-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 23 | Fmoc-His (trt) -His (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 24 | Fmoc-β-Ala-His (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 26 | Fmoc-β-ala-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 28 | FMOC-β-Ala-Leu-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 30 | FMOC-β-Ala-D-Leu-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 31 | Fmoc-lys (boc) -lys (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 32 | FMOC-β-Ala-Lys (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-Lys (Alloc) -Lys (Alloc) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 34 | Fmoc-β-Ala-Lys (Alloc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-meet-meh-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 36 | FMOC-β-Ala-Met-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 37 | Fmoc-Norn (BOC) -ORN (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 38 | Fmoc-β-Ala-Norn (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 39 | Fmoc-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 40 | FMOC-β-Ala-Phe-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 41 | Fmoc-d-phe-d-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 42 | FMOC-β-Ala-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 44 | Fmoc-β-Ala-Pro-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 46 | Fmoc-β-Ala-ser (TBU) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 48 | Fmoc-β-Ala-ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 50 | Fmoc-β-Ala-thr (TBU) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 51 | Fmoc-trp (boc) -trp (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 52 | Fmoc-β-Ala-Trp (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 53 | Fmoc-d-trp (boc) -d-trp (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-Ala-D-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-Tyr (Tbu) -Tyr (Tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 56 | Fmoc-β-Ala-Tyr (TBU) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 57 | Fmoc-D-Tyr (ET) -d-Tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (me) -tyr (jo) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 60 | Fmoc-β-Ala-Tyr (me) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 61 | Fmoc-val-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-Ala-Val-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 63 | Fmoc-d-cit-d-cit-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 64 | FMOC-β-Ala-D-Cit-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-ala-dab-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 66 | Fmoc- (3- (2-naftil) -d-ala) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-Ala-3- (2-naftil) -d-Ala-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-piridinil) -d-ala) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-Ala-3- (3-Piridinil) -D-Ala-Oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 70 | Fmoc- (4-cloro-d-phe) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 71 | FMOC-β-Ala-4-cloro-d-phe-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 72 | Fmoc- (d-4ph (tbucbm)) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 73 | FMOC-β-Ala-D-4PH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 74 | Fmoc-aph (l-hor) -ph (l-hor) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 75 | Fmoc-β-Ala-aph (l-hor) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 76 | Fmoc-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 78 | Fmoc-β-ala-eeea-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 79 | Fmoc-aib-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 80 | FMOC-β-Ala-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 82 | H-arg (PBF) -oh | 200115-86-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 86 | H-Homoarg (PBF) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 88 | HD-HOMOARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 90 | H-asn (trt) -oh | 132388-58-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 91 | Fmoc-ash-oh | 119062-05-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (OTBU) -oh | 3057-74-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 94 | H-cys (trt) -oh | 2799/7/7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 95 | H-cys (acm) -oh.hcl | 28798-28-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 97 | H-Gln (TRT) -oh | 102747-84-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 99 | H-Glu (OTBU) -OH.H2O | 2419-56-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 101 | H-his (trt) -oh | 35146-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 104 | H-Lys (BOC) -oh | 2418-95-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 105 | H-Lys (Alloc) -Oh | 6298/3/9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 106 | Fmoc-born-oh.hcl | 201046-57-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 107 | H-Norn (BOC) -Oh | 13650-49-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 110 | H-ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 114 | H-trp (boc) -oh | 146645-63-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 120 | HD-Tyr (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 121 | H-tyr (me) -oh.hcl | 67423-44-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 122 | Fmoc-d-4aph (cbm) -oh | 324017-22-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 123 | HD-4PH (TBUCBM) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 124 | Fmoc-lys (ipr) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 125 | H-Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
Al voltant de
Compensació
Gentolex proporciona productes de gran qualitat, si el client augmenta alguna qualitat del producte en el termini de temps requerit amb evidències suficients, proporcionarem una anàlisi i una avaluació necessàries per desencadenar els procediments de compensacions.
Producció
Les capacitats dels productes farmacèutics van assolir el grau de tones, les capacitats dels productes químics arriben a 100 tons+ grau, les capacitats estan ben equipades per donar servei als clients a tot el món.
Investigació i desenvolupament
Cada any, hi ha un pla configurat per l’equip de R + D per desenvolupar diferents productes nous, quan s’estableixin objectius, tots els membres de l’equip hauran de continuar amb la responsabilitat de KPI i amb la política d’incentius.
